Takeda launches Orzeyful in Japan and China for narcolepsy type 1

Orzeyful is now available in Japan and China as Takeda Pharmaceutical Company Limited TYO4502 NYSETAK launched its orexin-targeting tablet for narcolepsy type 1 on Thursday. The medicine covers adults in Japan and patients aged 16 and older in China.

Takeda’s launch announcement moves oveporexton from regulatory approval into commercial availability in its first markets. The company expects a U.S. launch in November, following completion of Drug Enforcement Administration scheduling.

Takeda is a global drugmaker headquartered in Japan, with a broad commercial business across rare diseases, neuroscience, oncology, vaccines and plasma-derived therapies.

Takeda’s NYSETAK depositary shares rose 2.65 per cent to US$19.01 at Wednesday’s New York close, marked 4:00 p.m. EDT by Google Finance, before the launch announcement.

The launch release gives no selling price, reimbursement terms or initial sales forecast for Japan or China. Commercial availability therefore establishes that physicians can prescribe the medicine, while leaving its initial revenue contribution unquantified.

Read more: Foresee Pharmaceuticals gains China approval for CAMCEVI 42 mg

Japan’s Ministry of Health, Labour and Welfare approved Orzeyful on Aug. 24, according to Takeda’s approval release. Its Japanese product overview specifies twice-daily dosing, starting at 1 milligram, with an increase permitted when tolerated and efficacy is insufficient.

Orexin Treatment Enters An Established Sleep Market

Orzeyful activates orexin receptor 2 to address the deficient signalling associated with narcolepsy type 1. The condition can cause excessive daytime sleepiness, sudden loss of muscle tone called cataplexy, disturbed nighttime sleep and hallucinations around sleep.

Jazz Pharmaceuticals plc NASDAQJAZZ provides a commercial comparison through its sleep-medicine business. In results released Aug. 3, Jazz reported second-quarter Xywav sales of US$471 million, up 13 per cent from a year earlier.

Jazz reported approximately 11,275 narcolepsy patients taking Xywav at the quarter’s end. Its sales also include idiopathic hypersomnia, so that revenue is broader than the narcolepsy type 1 indication covered by Takeda’s launch.

Takeda’s launch announcement cites Phase 3 improvements against placebo in wakefulness, sleepiness, cataplexy, disease severity and quality of life over 12 weeks, with p values below 0.001 across doses. It does not report a comparison against Xywav.

The FDA’s Aug. 5 approval notice describes two randomized, double-blind, placebo-controlled studies enrolling 273 adults. The agency reported better daytime wakefulness and improvements in other symptoms, without publishing numerical treatment differences in that notice.

“This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole,” Tiffany R. Farchione, the FDA’s psychiatry division director, said in the notice.

The FDA listed insomnia, urinary frequency, urinary urgency and increased saliva as common side effects. It also said the medicine should not be used with strong CYP3A inhibitors.

U.S. Availability Awaits Scheduling

The FDA approval is already in place for adults with narcolepsy type 1; the Japan and China launch is a separate commercial event. The FDA’s notice says lawful U.S. marketing follows the DEA’s scheduling decision.

In its Aug. 5 U.S. approval release, Takeda said that approval was not expected to significantly affect its consolidated forecast for the fiscal year ending March 31, 2027. That statement addressed the approval and supplied no launch revenue estimate for Japan or China.

Read more: Asahi Kasei wins FDA approval for HOVILPRI in refractory HSV

November 2026 is Takeda’s next stated launch window. Completion of DEA scheduling is the condition the company identifies before U.S. prescribing access begins.